Insomnia Symptoms and Risk for Unintentional Fatal Injuries—The HUNT Study

Laugsand, Lars Erik; Strand, Linn Beate; Vatten, Lars J.; Janszky, Imre; Bjørngaard, Johan Håkon

doi:10.5665/sleep.4170

Cited by 84 publications

(67 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26 Otros autores sugieren que el sueño reducido incrementa el riesgo de presentar aterosclerosis y enfermedades del corazón, 27,28 resistencia a la insulina, 29,30 obesidad 31 y enfermedades cardiometabólicas, 32 así como accidentes en el trabajo. 33 Acorde con lo anterior se puede decir que el sueño resulta esencial para la homeostasis del organismo.…”

Section: Sueño Y Sistema Inmuneunclassified

Sueño y sistema inmune

Rico-Rosillo

Vega-Robledo

2018

RAM

View full text Add to dashboard Cite

Este artículo debe citarse como: Rico-Rosillo MG, Vega-Robledo GB. Sueño y sistema inmune. Rev Alerg Mex. 2018;65(2):160-170 ORCID María Guadalupe Rico-Rosillo, ORCID: 0000-0002-3117-1617; Gloria Bertha Vega-Robledo, ORCID: 0000-0002-5816-1910 AbstractSleep is a process that occupies one third part of the life of the human being, and it is essential in order for the individual to be able to maintain body homeostasis. It emerges as an important regulator of the immune system since, during sleep, the necessary functions to maintain its balance are carried out. On the other hand, decreased sleep has deleterious eff ects that alter the metabolism and produce an increase in the secretion of C-reactive protein, interleukin (IL)-6 and tumor necrosis factor (TNF). These cytokines activate NF-κB; therefore, sleep disturbance can be a risk factor for the development of chronic infl ammatory and metabolic diseases. Pro-infl ammatory cytokines IL-1, IL-6 and TNF increase non-rapid eye movement sleep, whereas anti-infl ammatory cytokines such as IL-4 and IL-10 decrease it. Sleep can modify the immune system function by inducing changes in the hypothalamus-pituitary-adrenal axis and the sympathetic nervous system. In turn, the circadian rhythm of hormones such as cortisol and adrenaline, which have a nocturnal decrease, favors diff erent activities of the immune system. The purpose of the present review is to address diff erent aspects of sleep and their relationship with the immune system.

show abstract

Section: Sueño Y Sistema Inmuneunclassified

Sueño y sistema inmune

Rico-Rosillo

Vega-Robledo

2018

RAM

View full text Add to dashboard Cite

show abstract

“…20,21 Increased rates of work absenteeism, 22 and occupational and motor vehicle accidents have also been widely reported. 23,24 Persistent insomnia has been identified in multiple studies as a significant risk factor for the development of psychiatric disorders, especially mood disorder. 25,26 This condition is also associated with increased risk of relapse for depression and alcoholism, as well as adverse effects in chronic pain populations.…”

Section: Backg Roundmentioning

confidence: 99%

0395 Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

Sateia

Buysse

Krystal

et al. 2017

Sleep

View full text Add to dashboard Cite

Introduction:The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults. Methods: The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences. Literature reviews are provided for those pharmacologic agents for which sufficient evidence was available to establish recommendations. The AASM Board of Directors approved the final recommendations. Recommendations:The following recommendations are intended as a guideline for clinicians in choosing a specific pharmacological agent for treatment of chronic insomnia in adults, when such treatment is indicated. Under GRADE, a STRONG recommendation is one that clinicians should, under most circumstances, follow. A WEAK recommendation reflects a lower degree of certainty in the outcome and appropriateness of the patient-care strategy for all patients, but should not be construed as an indication of ineffectiveness. GRADE recommendation strengths do not refer to the magnitude of treatment effects in a particular patient, but rather, to the strength of evidence in published data. Downgrading the quality of evidence for these treatments is predictable in GRADE, due to the funding source for most pharmacological clinical trials and the attendant risk of publication bias; the relatively small number of eligible trials for each individual agent; and the observed heterogeneity in the data. The ultimate judgment regarding propriety of any specific care must be made by the clinician in light of the individual circumstances presented by the patient, available diagnostic tools, accessible treatment options, and resources.1. We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults. (WEAK) 2. We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK) 3. We suggest that clinicians use zaleplon as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK) 4. We suggest that clinicians use zolpidem as a treatment for sleep onset and sleep maintenance in...

show abstract

“…Также было показано, что сон влияет на процессы нейро-пластичности. На основании полученных данных сделан вывод, что расстройства сна (бессонница, синдром бес-покойных ног и гиперсомния) увеличивают риск развития инсульта, а пациентам, перенесшим инсульт, рекомендуют контролировать сон [7].…”

Section: нервно-психические расстройстваunclassified

“…У больных с выраженными когнитивными нарушениями наблюдается инверсия цикла «сон -бодр-ствование» с бессонницей в ночное время и сонливостью днем. Эти состояния сопровождаются поведенческими нарушениями и затрудняют реабилитацию больных [6][7].…”

Section: нервно-психические расстройстваunclassified